The FDA granted traditional approval to pembrolizumab (Keytruda) or its subcutaneous formulation for patients with ...

Daly ME, Simone CB II, Redman MW, et al. Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer ...

Chiaretti S, Piciocchi A, Skert C, et al. Ponatinib–blinatumomab or imatinib–chemotherapy for adult Ph-positive ALL. N Engl J Med. 2026;395:1483–94. A frontline chemotherapy-free regimen of ponatinib ...

Discover the key highlights and what to expect at ESMO 2026, including groundbreaking research and advancements in oncology.

On Oct. 19, the U.S. Food and Drug Administration (FDA) granted accelerated approval for dostarlimab (Jemperli) for adults with stage II or III locally advanced rectal cancer (LARC) that is ...

Men with metastatic hormone-sensitive prostate cancer who received androgen receptor pathway inhibitor doublets had longer ...

Aetna is expanding bundled prior authorization to all cancer types, combining medical oncology, radiation oncology, and imaging into one request. Oncologists and practice staff weigh in on whether it ...

Newsweek published its annual list of the best specialized hospitals in the world, including the best oncology practices. See ...

The FDA expanded the indication for nogapendekin alfa inbakicept-pmln plus BCG to include adults with BCG-unresponsive, ...

At WCLC 2026, three thoracic oncologists discuss first-line combinations, toxicity management, and subcutaneous amivantamab. Subcutaneous amivantamab cut infusion-related reactions to 13% to 16%, down ...

Results of the EPCORE FL-1 trial demonstrated that the chemotherapy-free combination of the CD3xCD20 bispecific antibody epcoritamab (Epkinly) with lenalidomide and rituximab (R 2) resulted in ...

Data from the phase 3 OPTIMA clinical trial suggest that genomic testing may help identify patients with estrogen receptor (ER)-positive, HER2-negative breast cancer who can safely avoid chemotherapy, ...